367 related articles for article (PubMed ID: 35170528)
1. Verification of hepatitis B-related hepatocellular carcinoma predictive models to evaluate the risk of HCC in patients with liver cirrhosis under antiviral treatment.
Huang X; Wang H; Zhang W; Gu E
Eur J Gastroenterol Hepatol; 2022 May; 34(5):546-552. PubMed ID: 35170528
[TBL] [Abstract][Full Text] [Related]
2. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.
Papatheodoridis GV; Sypsa V; Dalekos GN; Yurdaydin C; Van Boemmel F; Buti M; Calleja JL; Chi H; Goulis J; Manolakopoulos S; Loglio A; Voulgaris T; Gatselis N; Keskin O; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Idilman R; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2020 Jun; 72(6):1088-1096. PubMed ID: 31981727
[TBL] [Abstract][Full Text] [Related]
5. Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B.
Choi WM; Kim GA; Choi J; Choi GH; Lee YB; Sinn DH; Lim YS
Gut; 2024 Mar; 73(4):649-658. PubMed ID: 37813567
[TBL] [Abstract][Full Text] [Related]
6. Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis.
Jeon MY; Lee HW; Kim SU; Heo JY; Han S; Kim BK; Park JY; Kim DY; Ahn SH; Han KH
Hepatol Int; 2017 May; 11(3):268-276. PubMed ID: 28224351
[TBL] [Abstract][Full Text] [Related]
7. Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up.
Zhang W; Wang X; Wang Y; Zhao X; Duan W; Wang Q; Wu X; Kong Y; Ma H; You H; Ou X; Jia J
Medicine (Baltimore); 2017 Nov; 96(44):e8454. PubMed ID: 29095292
[TBL] [Abstract][Full Text] [Related]
8. [Risk analysis for hepatocellular carcinoma in patients with chronic hepatitis B-associated cirrhosis complicated by type 2 diabetes mellitus: a 5-year prospective cohort study].
Tang C; Hu C; Zhou Y; Song Y; Li M; Liao M; Sun J; Zhong C; Zhou L; Lin Z; Zhou Y
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Mar; 41(3):313-318. PubMed ID: 33849820
[TBL] [Abstract][Full Text] [Related]
9. Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients.
Kim JH; Ko SY; Choe WH; Kwon SY; Lee CH
Clin Mol Hepatol; 2013 Sep; 19(3):273-9. PubMed ID: 24133665
[TBL] [Abstract][Full Text] [Related]
10. HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Hepatitis Related Liver Cirrhosis Patients Undergoing Long-Term Effective Anti-Viral.
Chang KC; Lin MT; Wang JH; Hung CH; Chen CH; Chiu SY; Hu TH
Viruses; 2022 Nov; 14(12):. PubMed ID: 36560675
[TBL] [Abstract][Full Text] [Related]
11. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease.
Cho JY; Paik YH; Sohn W; Cho HC; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Gut; 2014 Dec; 63(12):1943-50. PubMed ID: 24615378
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients.
Wu X; Xu X; Zhou J; Sun Y; Ding H; Xie W; Chen G; Ma A; Piao H; Wang B; Chen S; Meng T; Ou X; Yang HI; Jia J; Kong Y; You H
Clin Mol Hepatol; 2023 Jul; 29(3):747-762. PubMed ID: 37165622
[TBL] [Abstract][Full Text] [Related]
13. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
[TBL] [Abstract][Full Text] [Related]
14. Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy.
Wu X; Zhou J; Sun Y; Ding H; Chen G; Xie W; Piao H; Xu X; Jiang W; Ma H; Ma A; Chen Y; Xu M; Cheng J; Xu Y; Meng T; Wang B; Chen S; Shi Y; Kong Y; Ou X; You H; Jia J
Hepatol Int; 2021 Feb; 15(1):82-92. PubMed ID: 33460002
[TBL] [Abstract][Full Text] [Related]
15. Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy.
Oh JH; Lee HW; Sinn DH; Park JY; Kim BK; Kim SU; Kim DY; Ahn SH; Kang W; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Paik YH
Hepatol Int; 2021 Aug; 15(4):892-900. PubMed ID: 34260013
[TBL] [Abstract][Full Text] [Related]
16. Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B.
Sohn W; Cho JY; Kim JH; Lee JI; Kim HJ; Woo MA; Jung SH; Paik YH
Clin Mol Hepatol; 2017 Jun; 23(2):170-178. PubMed ID: 28506056
[TBL] [Abstract][Full Text] [Related]
17. Effects of Virologic Response to Treatment on Short- and Long-term Outcomes of Patients With Chronic Hepatitis B Virus Infection and Decompensated Cirrhosis.
Jang JW; Choi JY; Kim YS; Yoo JJ; Woo HY; Choi SK; Jun CH; Lee CH; Sohn JH; Tak WY; Lee YR; Han KH
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1954-1963.e3. PubMed ID: 29753085
[TBL] [Abstract][Full Text] [Related]
18. The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B.
Kim BG; Park NH; Lee SB; Jeon S; Park JH; Jung SW; Jeong ID; Bang SJ; Shin JW
Liver Int; 2018 Dec; 38(12):2269-2276. PubMed ID: 30052303
[TBL] [Abstract][Full Text] [Related]
19. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy.
Kim JH; Kim YD; Lee M; Jun BG; Kim TS; Suk KT; Kang SH; Kim MY; Cheon GJ; Kim DJ; Baik SK; Choi DH
J Hepatol; 2018 Nov; 69(5):1066-1073. PubMed ID: 30075230
[TBL] [Abstract][Full Text] [Related]
20. Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response.
Kim GA; Han S; Kim HD; An J; Lim YS
J Viral Hepat; 2017 Nov; 24(11):990-997. PubMed ID: 28499070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
